Coolcat's Triple Play

11/22/2002 12:00 am EST

Focus:

Kevin Kennedy

Publisher, Coolcat Explosive Small Cap Growth Stock Report

Through several proprietary screens, Kevin Kennedy isolates low-priced, high-momentum stocks with the best potential for large gains. His service, The Coolcat Explosive Small Cap Growth Stock Report, was ranked by The Hulbert Financial Digest as the #1 investment newsletter for 2001 with a gain of 77.7%. His latest buys are medical plays.

America Service Group (ASGR NASDAQ) is up from a low of $2.87. The stock’s high is $15.34. The company is involved in medical and dental. America Service provides correctional healthcare services in the US. The company, through its subsidiaries, provides a wide range of healthcare and pharmacy programs to government agencies for the medical care of inmates.

VaxGen (VXGN NASDAQ) is up from a low of $4.81 and just below its high of $15.95.  This biotech company is focused on the commercial development of biologic products for the prevention and treatment of human infectious diseases and is currently developing vaccines against HIV/AIDS and anthrax. VaxGen is the only company with HIV/AIDS vaccine candidates in Phase III clinical trials. The two trials, involving nearly 8,000 volunteers are designed to determine if VaxGen's AIDSVAX investigational vaccines can prevent humans from becoming infected with HIV, the virus that causes AIDS. VaxGen is also developing an anthrax vaccine for the National Institutes of Health.”

Kennedy also maintains a list of “super 7 stocks” which meet strict criteria including high relative strength, a recent new high, strong volume, and a breakout from a base. The latest issue to meet these qualifications is Hi-Tech Pharmacal (HITK NASDAQ), a specialty pharmaceutical company developing branded and generic products. The company specializes in difficult-to-manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic and inhalation products. The company is also a leading developer of branded products for the diabetes marketplace.”

Related Articles on